Therefore, we hypothesize that the overproduction of antibodies directed against D1R, as can be seen in our cohort (Table 2), might interfere with dopamine binding to its receptor or directly affect D1R signaling pathways and, thus, contribute to cognitive and emotional disturbances reported in COVID-19 patients. The gene discussed is DRD1; the disease is COVID-19.